Please login to the form below
vulvovaginal candidiasis
This page shows the latest vulvovaginal candidiasis news and features for those working in and with pharma, biotech and healthcare.
FDA approves Scynexis’ Brexafemme for recurrent vulvovaginal candidiasis
The US Food and Drug Administration (FDA) has approved a second indication for Scynexis’ Brexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC). ... The decision makes Brexafemme, a novel oral
Latest news
-
Janssen's first-in-class diabetes drug Invokana wins US approval
The most common side effects of Invokana are vaginal yeast infection (vulvovaginal candidiasis) and urinary tract infection.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- AstraZeneca’s mild combination asthma reliever approved in UK
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
